Thalidomide therapy for myelofibrosis with myeloid metaplasia (pages 1974–1984)
Deborah A. Thomas, Francis J. Giles, Maher Albitar, Jorge E. Cortes, Srdan Verstovsek, Stefan Faderl, Susan M. O'Brien, Guillermo Garcia-Manero, Michael J. Keating, Sherry Pierce, Jerome Zeldis and Hagop M. Kantarjian
Article first published online: 31 MAR 2006 | DOI: 10.1002/cncr.21827
Patients who had myelofibrosis with myeloid metaplasia (MMM) received treatment with dose escalated thalidomide in a Phase II clinical trial. Detailed assessments of angiogenesis (including serum levels and bone marrow microvessel density) were performed. The results indicated that thalidomide warrants further evaluation in patients with MMM, particularly in combination regimens, along with the investigation of newer analogs.